Individualized Dosing of Infliximab Reduces Variability in Exposure and Endoscopic Improvement Among Patients With Ulcerative Colitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Pharmaceutics
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis
Pharmaceutics 2021 Oct 06;13(10)1623, R Faelens, Z Wang, T Bouillon, P Declerck, M Ferrante, S Vermeire, E DreesenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.